In a report issued today, the Government Accountability Office recommended that the Health Resources and Services Administration take additional steps to ensure contract pharmacies comply with 340B drug savings program requirements. Requested by Republican leaders of the House Energy and Commerce Committee, the report reviews the use of contract pharmacies in the 340B program. HRSA concurs in the report with GAO recommendations that it issue guidance on preventing duplicate discounts under Medicaid managed care and assess compliance, and issue more specific guidance regarding contract pharmacy oversight. The agency also agreed with a GAO recommendation to issue guidance on the length of time covered entities must look back following an audit to identify the full scope of noncompliance identified during the audit. HRSA disagreed in the report with a GAO recommendation that it require covered entities to register contract pharmacies for each site of the entity for which a contract exists, and with recommendations that audited covered entities provide certain additional information.

Related News Articles

Headline
The U.S. District Court for the District of Rhode Island Sept. 30 denied motions from AbbVie and Novartis seeking a preliminary injunction against the state’s…
Headline
The anticipated burdens on hospitals to comply with the Health Resources and Services Administration’s 340B Rebate Pilot Program far exceed the agency’s…
Headline
The U.S. District Court for the District of Maine today issued an order denying preliminary injunctions requested by AbbVie and Novartis in legal challenges…
Headline
The AHA commented Sept. 15 on the Centers for Medicare & Medicaid Services calendar year 2026 outpatient prospective payment system and ambulatory surgical…
Headline
The United States Court of Appeals for the Fifth Circuit Sept. 12 affirmed a Mississippi Court’s decision to deny AbbVie’s request for a preliminary injunction…
Headline
The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts…